Y-mAbs Therapeutics presents translational pharmacokinetics data of GD2-SADA

Y-mAbs Therapeutics (YMAB) announced the presentation of preclinical and translational pharmacokinetics data of GD2-SADA in a poster at the Society of Nuclear Medicine & Molecular Imaging Mid-Winter and American College of Nuclear Medicine Annual Meeting being held on January 30 to February 1, 2025 in Anaheim, California. The poster titled “Preclinical and Translational Pharmacokinetics of GD2-SADA, a Self-Assembling and Disassembling Bispecific Fusion Protein for Pretargeted Radioimmunotherapy” characterizes the plasma levels of GD2-SADA in animal models over time and a range of doses, while also presenting the concentration- and time-dependent equilibrium between GD2-SADA tetramers and monomers in vitro. Incorporated within translational PK simulations, the data have provided important insights into GD2-SADA tumor exposure and plasma elimination, key parameters for minimizing systemic exposure to 177Lutetium-DOTA. Abstract Title: “Preclinical and translational pharmacokinetics of GD2-SADA, a self-assembling and disassembling bispecific fusion protein for pretargeted radioimmunotherapy”: Researchers at Memorial Sloan Kettering Cancer Center, including Dr. Nai-Kong Cheung, developed the SADA technology for radioimmunotherapy, which is exclusively licensed by MSK to Y-mAbs. Dr. Cheung has intellectual property rights and interests in the technology, and as a result of this licensing arrangement, MSK has institutional financial interests in the technology.